Form 4: Alkermes Executive Exercises Stock Options and Sells Shares Under 10b5-1 Plan

Craig C. Hopkinson, EVP R&D and Chief Medical Officer at Alkermes plc, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Craig C. Hopkinson, an executive at Alkermes plc, executed multiple transactions involving the company's stock on December 9, 2024.
• Hopkinson exercised stock options to acquire a total of 48,997 ordinary shares at prices ranging from $19.34 to $26.82.
• These options were exercised under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Concurrently, Hopkinson sold 61,151 ordinary shares at a weighted average price of $32.0748, also under the same 10b5-1 plan.
• Following these transactions, Hopkinson's direct holdings of Alkermes ordinary shares decreased to 47,576.

Sentiment

Score: 5

Explanation: The document reflects routine transactions under a pre-arranged plan, indicating a neutral sentiment. There is no indication of positive or negative news.

Risks

• The sale of a significant number of shares by an executive could be perceived negatively by the market, although it was conducted under a pre-arranged trading plan.

Industry Context

This type of transaction is common for executives who receive stock options as part of their compensation, and the use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies like Alkermes to manage their stock holdings and avoid insider trading concerns.
• Similar transactions are frequently seen at comparable pharmaceutical and biotech companies such as Biogen, Vertex Pharmaceuticals, and Regeneron, where executives often exercise stock options and sell shares as part of their compensation and financial planning.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as the sale of shares by an executive could slightly increase the supply of shares in the market.

Key Dates

Keywords

Alkermes, stock options, insider trading, Rule 10b5-1, executive compensation, share sale, Craig C. Hopkinson